Download PDF
Der Nuklearmediziner 2012; 35(03): 161-166
DOI: 10.1055/s-0032-1321823
Diagnostik und Therapie von Skeletterkrankungen – Update 2012
© Georg Thieme Verlag KG Stuttgart · New York

SPECT/CT und Fluorid-PET/CT bei Metastasen des Skelettes und primären malignen Knochentumoren

SPECT/CT and Fluoride-PET/CT in Bone Metastases and Primary Malignant Bone Tumors
K. Strobel
1   Institut für Nuklearmedizin und Röntgendiagnostik, Luzerner Kantonsspital, Luzern, Schweiz
› Author Affiliations
Further Information

Publication History

Publication Date:
11 September 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Ergänzung der planaren Szintigrafie durch ein gezieltes SPECT/CT führt in ca. 90% der Fälle von unklaren Anreicherungen zu einer definitiven Diagnose und stellt derzeit die Hauptanwendung der SPECT/CT beim Staging von Malig­nompatienten dar. Die Implementierung eines Mehrfeld-SPECT/CT des Stammskeletts in das Standardprotokoll bei Metastasensuche ist eine alternative Möglichkeit, um die Genauigkeit der Skelettszintigrafie zu verbessern. Die FDG-PET/CT hat die Skelettszintigrafie bei vielen Tumoren, vor allem Bronchuskarzinom, GI-Tumoren und High-risk-Mammakarzinom ersetzt. Besonders beim Prostatakarzinom ist die Fluorid-PET/CT die derzeit genaueste Methode zur Knochenmetastasensuche und auch der SPECT/CT überlegen. Der breitere Einsatz der Fluorid-PET/CT ist derzeit noch durch die limitierte Verfügbarkeit und ungeklärte Kostenerstattungsfrage eingeschränkt.

Abstract

The supplementation of the planar bone scintigraphy with a targeted SPECT/CT leads to a definite diagnosis in approx 90% of unclear uptakes and represents the main application of SPECT/CT in cancer patients. The implementation of multiple field SPECT/CT of the axial skeleton into the standard bone scan protocol is an alternative possibility to increase the accuracy of bone scintigraphy. FDG-PET/CT has replaced conventional bone scintigraphy in many tumors, especially lung, GI cancer and high-risk breast cancer. In prostate cancer fluoride-PET/CT is the most accurate modality for the detection of bone metastases and superior to SPECT/CT. The more frequent use of fluoride-PET/CT is currently limited by the restricted availability and unclear reimbursement.

Schlüsselwörter

SPECT/CT - Skelettszintigrafie - Fluorid-PET/CT - FDG-PET/CT - Kochenmetastasen - Knochentumoren

Key words

SPECT/CT - bone scintigraphy - fluoride-PET/CT - FDG-PET/CT - bone metastases - bone tumor
 

  • Literatur

  • 1 Abe K, Sasaki M, Kuwabara Y et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005; 19: 573-579
    CrossrefPubMedGoogle Scholar
  • 2 Brenner W, Kh Bohuslavizki, Eary Jf. PET imaging of osteosarcoma. J Nucl Med 2003; 44: 930-942
    PubMedGoogle Scholar
  • 3 Cook Gj, Houston S, Rubens R et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-3379
    PubMedGoogle Scholar
  • 4 Dose-Schwarz J, Mahner S, Schirrmacher S et al. Detection of metastases in breast cancer patients: comparison of FDG PET with chest X-ray, bone scintigraphy and ultrasound of the abdomen. Nuklearmedizin 2008; 47: 97-103
    PubMedGoogle Scholar
  • 5 Du Y, Cullum I, Illidge Tm et al. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007; 25: 3440-3447
    CrossrefPubMedGoogle Scholar
  • 6 Even-Sapir E, Metser U, Mishani E et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47: 287-297
    PubMedGoogle Scholar
  • 7 Franzius C, Ku Juergens, Vormoor J. PET/CT with diagnostic CT in the evaluation of childhood sarcoma. AJR Am J Roentgenol 186: 581 author reply 2006; 581-582
    PubMedGoogle Scholar
  • 8 Franzius C, Sciuk J, Daldrup-Link He et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000; 27: 1305-1311
    CrossrefPubMedGoogle Scholar
  • 9 Fujimoto R, Higashi T, Nakamoto Y et al. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Ann Nucl Med 2006; 20: 399-408
    CrossrefPubMedGoogle Scholar
  • 10 Hahn S, Heusner T, Kummel S et al. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol 52: 1009-1014
    PubMedGoogle Scholar
  • 11 Helyar V, Hk Mohan, Barwick T et al. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging 37: 706-713
    PubMedGoogle Scholar
  • 12 Horger M, Sm Eschmann, Pfannenberg C et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR Am J Roentgenol 2004; 183: 655-661
    CrossrefPubMedGoogle Scholar
  • 13 Ito S, Kato K, Ikeda M et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 2007; 48: 889-895
    CrossrefPubMedGoogle Scholar
  • 14 Ndlovu X, George R, Ellmann A et al. Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies?. Nucl Med Commun 31: 659-665
    PubMedGoogle Scholar
  • 15 Romer W, Nomayr A, Uder M et al. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med 2006; 47: 1102-1106
    PubMedGoogle Scholar
  • 16 Schirrmeister H, Glatting G, Hetzel J et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001; 42: 1800-1804
    PubMedGoogle Scholar
  • 17 Segall G, Delbeke D, Stabin Mg et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med 51: 1813-1820
    PubMedGoogle Scholar
  • 18 Song Jw, Oh Ym, Shim Ts et al. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer 2009; 65: 333-338
    CrossrefPubMedGoogle Scholar
  • 19 Strobel K, Burger C, Seifert B et al. Characterization of focal bone lesions in the axial skeleton: performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT. AJR Am J Roentgenol 2007; 188: W467-W474
    CrossrefPubMedGoogle Scholar
  • 20 Tateishi U, Morita S, Taguri M et al. A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med 24: 523-531
    PubMedGoogle Scholar
  • 21 Treglia G, Salsano M, Stefanelli A et al. Diagnostic accuracy of (1)(8)F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis. Skeletal Radiol 41: 249-256
    PubMedGoogle Scholar
  • 22 Utsunomiya D, Shiraishi S, Imuta M et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology 2006; 238: 264-271
    CrossrefPubMedGoogle Scholar
  • 23 Withofs N, Grayet B, Tancredi T et al. (1)(8)F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 32: 168-176
    PubMedGoogle Scholar
  • 24 Yen Rf, Chen Cy, Cheng Mf et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun 31: 637-645
    PubMedGoogle Scholar
  • 25 Zhao Z, Li L, Li F et al. Single photon emission computed tomography/spiral computed tomography fusion imaging for the diagnosis of bone metastasis in patients with known cancer. Skeletal Radiol 39: 147-153
    PubMedGoogle Scholar